Although pulmonary rehabilitation for chronic obstructive pulmonary disease (COPD) is linked to better survival, a large study of fee-for-service (FFS) Medicare patients show it is underused, with less than 2% of those studied taking part in a 3-month program.
Pulmonary rehabilitation significantly lowers the risk of death after hospitalization for chronic obstructive pulmonary disease (COPD), but it is rarely used, according to a large study and an accompanying editorial released Tuesday.
The retrospective study, published in JAMA, examined a large dataset of patients enrolled in fee-for-service Medicare in 4446 hospitals across the United States in 2014.1 Investigators looked at the association between the start of pulmonary rehabilitation within 90 days of hospital discharge and 1-year survival rates. They noted the severity of the problem: one study said that between 2008 and 2014, mortality for Medicare patients within 1 year of discharge for COPD was estimated at 26%.
In their study of 197,376 patients (mean age, 76.9 years; 115,690 [58.6%] women), just 2721 patients (1.5%) initiated pulmonary rehabilitation within 90 days of discharge. Patients completed a median of 9 sessions (interquartile range, 4-14) during the 90-day period.
Initiation of pulmonary rehabilitation within 90 days was associated with a lower risk of death over 1 year, with 198 deaths (7.3%) among patients who began pulmonary rehabilitation within 90 days. Patients who started rehabilitation after the 90 days or did not begin at all had higher mortality, with 38,104 deaths (19.6%).
Lower mortality was seen when pulmonary rehabilitation was initiated early, within 30 days of discharge (ARD, −4.6%; hazard ratio [HR], 0.74; 95% CI, 0.67-0.82) or 61 to 90 days after discharge (ARD, −11.1%; HR, 0.40; 95% CI, 0.30-0.54).
Participation in every 3 additional pulmonary rehabilitation sessions in the first 90 days after discharge was associated with a lower hazard ratio for death (HR, 0.91; 95% CI, 0.85 to 0.98; P = .01).
Noting the low rates of participation, the authors wrote that “the results of this study reinforce the importance of developing more effective strategies for increasing participation in rehabilitation.” Pulmonary rehabilitation is particularly important for women, those with lower socioeconomic status, and members of minority groups.
COPD is the fourth leading cause of death in the United States and is estimated to affect more than 16 million people. Current guidelines, such as the 2015 ATS/ERS joint policy statement, recommend pulmonary rehabilitation after acute COPD exacerbations.
In an accompanying editorial, the authors noted several reasons for the underuse of pulmonary rehabilitation.2 Health care providers often do not recommend the service due to a lack of incentives, such as financial reimbursement linked to patient outcomes, or national care quality metrics. In addition, pulmonary rehabilitation programs are “typically underfunded and underresourced” while the use of bronchodilators are endorsed, they wrote.
Even patients who are referred do not follow through on a program; this may be due to barriers to access such as transportation issues, geography, or comorbidities. Indeed, in this study, patients who attended rehabilitation were more likely to be younger, live close to a program, to be white men, and healthier.
The study had several limitations: there may have been residual bias due to confounders that could not be measured. And although the study included proxies for disease severity, such as the use of home oxygen, pulmonary function tests or other physiologic measures were not available. In addition, the claims data did not include other components of rehabilitation delivered during the sessons, such as patient and caregiver education, exercise training, or smoking cessation.
References
1. Lindenauer PK, Stefan MS, Pekow PS, et al. Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among Medicare beneficiaries [published online May 12, 2020]. JAMA. doi:10.1001/jama.2020.4437
2. Rochester CL, Holland AE. Pulmonary rehabilitation and improved survival for patients with COPD [published online May 12, 2020]. JAMA. doi:10.1001/jama.2020.4436
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More